On April 13, 2011, the Food and Drug Administration (FDA) proposed a rule that, if finalized, will expand the scope and consequences of clinical investigator disqualifications. Under the proposed rule, a clinical investigator, including a sponsor-investigator, disqualified pursuant to FDA regulations (21 C.F.R. Parts 312, 511, or 812) will be ineligible to receive specified test articles. Thus, under the proposed rule, a disqualified investigator would not be allowed to conduct or participate in clinical investigation or obtain a marketing permit for any FDA-regulated products, rather than just the specific kind of test article that was the subject of the disqualification. This increases the importance of a disqualification because a disqualified investigator would no longer be allowed to participate in research supporting marketing applications for any drugs, biologics, devices, new animal drugs, foods, including dietary supplements that bear a nutrient content claim or a health claim, infant formulas, food and color additives, and tobacco products. The FDA is accepting comments on the proposed rule through July 12, 2011.
Click the link below to read the full alert.